137 related articles for article (PubMed ID: 33675738)
1. Single quad mass analyzer coupled UPLC method for impurity profile of Brimonidine tartrate and Timolol maleate: Application in their binary mixture ophthalmic formulation.
Kondra S; Akula Thukaram B; Gowrisankar D; Krishnamanjari PA; Raju Dantuluri HSN; Maganti S
Ann Pharm Fr; 2021 Nov; 79(6):617-639. PubMed ID: 33675738
[TBL] [Abstract][Full Text] [Related]
2. Assay of tirofiban and identification of oxidative impurity in aqueous injection by using UPLC-PDA/QDa detectors.
Murali Krishnam Raju P; Shyamala P; Venkata Narayana B; Kondra S; Mantena BPV
Ann Pharm Fr; 2022 Jan; 80(1):35-47. PubMed ID: 34153240
[TBL] [Abstract][Full Text] [Related]
3. A fast, validated UPLC method coupled with PDA-QDa detectors for impurity profiling in betamethasone acetate and betamethasone phosphate injectable suspension and isolation, identification, characterization of two thermal impurities.
Murali Krishnam Raju P; Shyamala P; Venkata Narayana B; Dantuluri HSNR; Bhupatiraju RV
Ann Pharm Fr; 2022 Nov; 80(6):837-852. PubMed ID: 35489418
[TBL] [Abstract][Full Text] [Related]
4. Development of a rapid and validated stability-indicating UPLC-PDA method for concurrent quantification of impurity profiling and an assay of ipratropium bromide and salbutamol sulfate in inhalation dosage form.
Kondra S; Pawar AKM; Bapuji AT; Shankar PDS
Ann Pharm Fr; 2023 Mar; 81(2):300-314. PubMed ID: 36126754
[TBL] [Abstract][Full Text] [Related]
5. A New UPLC Method with Chemometric Design-Optimization Approach for the Simultaneous Quantitation of Brimonidine Tartrate and Timolol Maleate in an Eye Drop Preparation.
Büker E; Dinç E
J Chromatogr Sci; 2017 Feb; 55(2):154-161. PubMed ID: 27881494
[TBL] [Abstract][Full Text] [Related]
6. A novel and rapid validated stability-indicating UPLC method of related substances for dorzolamide hydrochloride and timolol maleate in ophthalmic dosage form.
Sharma N; Rao SS; Reddy AM
J Chromatogr Sci; 2012 Oct; 50(9):745-55. PubMed ID: 22562819
[TBL] [Abstract][Full Text] [Related]
7. A validated stability-indicating HPLC method for determination of brimonidine tartrate in BRI/PHEMA drug delivery systems.
Sun J; Zhang X; Huang T
Chem Cent J; 2017 Jul; 11(1):62. PubMed ID: 29086854
[TBL] [Abstract][Full Text] [Related]
8. Multicenter, Randomized, Investigator-Masked Study Comparing Brimonidine Tartrate 0.1% and Timolol Maleate 0.5% as Adjunctive Therapies to Prostaglandin Analogues in Normal-Tension Glaucoma.
Mizoue S; Nitta K; Shirakashi M; Nitta A; Yamabayashi S; Kimura T; Ueda T; Takeda R; Matsumoto S; Yoshikawa K
Adv Ther; 2017 Jun; 34(6):1438-1448. PubMed ID: 28508306
[TBL] [Abstract][Full Text] [Related]
9. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
LeBlanc RP
Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
[TBL] [Abstract][Full Text] [Related]
10. Chick chorioallantoic membrane model for in ovo evaluation of timolol maleate-brimonidine tartrate ocular inserts.
Ravindran VK; Repala S; Subadhra S; Appapurapu AK
Drug Deliv; 2014 Jun; 21(4):307-14. PubMed ID: 24134746
[TBL] [Abstract][Full Text] [Related]
11. Prolonged central nervous system and respiratory depression in preterm neonates after exposure to brimonidine tartrate and timolol maleate ophthalmic drops.
Azarcon CP; Santiago DE
GMS Ophthalmol Cases; 2020; 10():Doc25. PubMed ID: 32676270
[No Abstract] [Full Text] [Related]
12. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
[TBL] [Abstract][Full Text] [Related]
13. A Stability-Indicating UPLC Method for the Determination of Potential Impurities and Its Mass by a New QDa Mass Detector in Daclatasvir Drug Used to Treat Hepatitis C Infection.
Jagadabi V; Nagendra Kumar PV; Mahesh K; Pamidi S; Ramaprasad LA; Nagaraju D
J Chromatogr Sci; 2019 Jan; 57(1):44-53. PubMed ID: 30169761
[TBL] [Abstract][Full Text] [Related]
14. Brimonidine and timolol concentrations in the human vitreous and aqueous humors after topical instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution: An interventional study.
Orii Y; Kunikane E; Yamada Y; Morioka M; Iwasaki K; Arimura S; Mizuno A; Inatani M
PLoS One; 2022; 17(12):e0277313. PubMed ID: 36454807
[TBL] [Abstract][Full Text] [Related]
15. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma.
Konstas AG; Stewart WC; Topouzis F; Tersis I; Holmes KT; Stangos NT
Am J Ophthalmol; 2001 Jun; 131(6):729-33. PubMed ID: 11384568
[TBL] [Abstract][Full Text] [Related]
16. Ocular and Systemic Pharmacokinetics of Brimonidine and Timolol After Topical Administration in Rabbits: Comparison Between Fixed-Combination and Single Drugs.
Suzuki G; Kunikane E; Shinno K; Kozai S; Kurata M; Kawamura A
Ophthalmol Ther; 2020 Mar; 9(1):115-125. PubMed ID: 31953739
[TBL] [Abstract][Full Text] [Related]
17. A UPLC method development and validation study of Upadacitinib and its impurities in extended - Release oral tablet dosage forms.
Nimmagadda RL; Gummadi S
Ann Pharm Fr; 2024 Mar; ():. PubMed ID: 38554818
[TBL] [Abstract][Full Text] [Related]
18. Isolation, Identification, and Characterisation of Degradation Products and the Development and Validation of a Stability-Indicating Method for the Estimation of Impurities in the Tolterodine Tartrate Formulation.
Prakash L; Himaja M; Vasudev R
Sci Pharm; 2015; 83(1):65-83. PubMed ID: 26839802
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous determination of timolol maleate in combination with some other anti-glaucoma drugs in rabbit aqueous humor by high performance liquid chromatography-tandem mass spectroscopy.
Hassib ST; Elkady EF; Sayed RM
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jun; 1022():109-117. PubMed ID: 27085020
[TBL] [Abstract][Full Text] [Related]
20. Forced degradation and impurity profiling: recent trends in analytical perspectives.
Jain D; Basniwal PK
J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
